Skip to content
Archive

KOLINPHARMA®: first patent obtained for Xinprox®

KOLINPHARMA® S.p.A. is pleased to announce that it has obtained the first patent for XINPROX®.

XINPROX®, studied and developed for prostate well-being, is a food supplement whose formulation is based on very high-quality, technologically advanced raw materials supported by scientific studies, such as pollen extract, quercetin, alpha-lipoic acid and L-tryptophan.

Kolinpharma®'s total number of patents thus rises to 46: 7 in Italy, 6 in the USA, 1 in Israel and 32 in the main European countries.

Rita Paola Petrelli, President of KOLINPHARMA®, commented: “We are proud to announce that we have obtained the first patent for XINPROX®, which once again shows the soundness of our formulations and of the work done by our Research and Development department and by the whole company. [...] Research is one of our strengths, and for this reason we intend to keep investing in and enhancing our products to offer our customers and patients scientifically validated solutions. A patent stands for synergy, uniqueness and innovation”.

Read the press release

More news

  1. KOLINPHARMA® signs an agreement with ASTAREAL® AB to distribute its products in the Asian market
  2. Kolinpharma® for gender equality at PMIHeroes
  3. KOLINPHARMA®: pubblicati Bilancio di Sostenibilità e la prima Relazione di Impatto 2021
Archive